Nanoparticulate and controlled release compositions comprising a cephalosporin
The present invention provides a composition comprising cephalosporin useful in the treatment and prevention of a bacterial infection. In one embodiment, the composition comprises nanoparticulate particles comprising cephalosporin and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers cephalosporin in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of a bacterial infection.
1 . A stable nanoparticulate composition comprising: (A) particles comprising a cephalosporin, said particles having an effective average particle size of less than about 2000 nm in diameter; and (B) at least one surface stabilizer.
2 . The composition of claim 1 , wherein said cephalosporin is cefdinir or a salt, derivative, prodrug, or polymorph thereof, said cefdinir being present either as a single substantially optically pure enantiomer thereof or as a mixture of enantiomers thereof.
3 . The composition of claim 2 , wherein said particles are in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi amorphous phase, or a mixture thereof.
4 . The composition of claim 2 further comprising one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
5 . The composition of claim 2 , wherein the surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, and an ionic surface stabilizer.
6 . The composition of claim 2 comprising:
(a) about 50 to about 500 g/kg cefdinir;
(b) about 10 to about 70 g/kg hypromellose;
(c) about 1 to about 10 g/kg docusate sodium;
(d) about 100 to about 500 g/kg sucrose;
(e) about 1 to about 40 g/kg sodium lauryl sulfate;
(f) about 50 to about 400 g/kg lactose monohydrate;
(g) about 50 to about 300 g/kg silicified microcrystalline cellulose;
(h) about 20 to about 300 g/kg crospovidone; and
(i) about 0.5 to about 5 g/kg magnesium stearate.
7 . The composition of claim 6 , further comprising a coating agent.
8 . The composition of claim 2 comprising:
(a) about 100 to about 300 g/kg cefdinir;
(b) about 30 to about 50 g/kg hypromellose;
(c) about 0.5 to about 10 g/kg docusate sodium;
(d) about 100 to about 300 g/kg sucrose;
(e) about 1 to about 30 g/kg sodium lauryl sulfate;
(f) about 100 to about 300 g/kg lactose monohydrate;
(g) about 50 to about 200 g/kg silicified microcrystalline cellulose;
(h) about 50 to about 200 g/kg crospovidone; and
(i) about 0.5 to about 5 g/kg magnesium stearate.
9 . The composition of claim 8 , further comprising a coating agent.
10 . The composition of claim 2 , additionally comprising one or more active compounds useful for the prevention and treatment of a bacterial infection.
11 . The composition of claim 2 wherein said particles contain a reservoir which contains cefdinir, or a salt, derivative, prodrug, or polymorph thereof, said reservoir being enclosed by a semi-permeable membrane which allows for water to be imbibed into said particles, thus generating pressure which forces said cephalosporin out of said particles.
12 . The composition of claim 11 wherein said reservoir comprises also an osmotic agent.
13 . A method of preparing the composition of claim 2 comprising contacting particles comprising said cefdinir, or a salt, derivative, prodrug, or polymorph thereof, with at least one surface stabilizer for a period of time and under conditions sufficient to provide a nanoparticulate composition comprising said cefdinir, or a salt, derivative, prodrug, or polymorph thereof, having an effective average particle size of less than about 2000 nm in diameter.
14 . A method of preventing and/or treating a bacterial infection comprising administering a composition according to claim 2 .
15 . A pharmaceutical composition comprising a first component of active ingredient-containing particles and at least one subsequent component of active ingredient-containing particles, wherein at least one of said components comprises particles wherein a cephalosporin is the active ingredient and at least one of said components further comprises a modified release coating, a modified release matrix material, or both, such that the composition, following oral delivery to a subject, delivers the active ingredient in a continuous, bimodal or multimodal manner.
16 . The composition of claim 15 wherein said cephalosporin is cefdinir or a salt, derivative, prodrug, or polymorph thereof.
17 . The composition of claim 16 wherein the particles containing cefdinir or a salt, derivative, prodrug, or polymorph thereof comprise nanoparticles which comprise said cefdinir or a salt, derivative, prodrug, or polymorph thereof.
18 . The composition of claim 16 wherein the particles containing cefdinir or a salt, derivative, prodrug, or polymorph thereof are nanoparticles which comprise said cefdinir or a salt, derivative, prodrug, or polymorph thereof.
19 . The composition of claim 16 wherein each component comprises particles in which the active ingredient is cefdinir or a salt, derivative, prodrug, or polymorph thereof.
20 . The composition of claim 16 , wherein the first component comprises an immediate release component and at least one subsequent component comprises a modified release component.
21 . The composition of claim 16 , wherein the active ingredient-containing particles are erodable.
22 . The composition of claim 16 wherein said composition further comprises an enhancer.
23 . A dosage form comprising the composition of claim 16 .
24 . The dosage form of claim 23 comprising a blend of active ingredient-containing particles contained within a hard gelatin or soft gelatin capsule.
25 . The dosage form of claim 23 , wherein the active ingredient-containing particles are in the form of mini-tablets and the capsule contains a mixture of said mini-tablets.
26 . The dosage form of claim 23 in the form of tablet.
27 . The dosage form of claim 23 wherein the particles comprising cefdinir, or a salt, derivative, prodrug, or polymorph thereof, are provided in a rapidly dissolving dosage form.
28 . The dosage form of claim 26 wherein the tablet is a fast-melt tablet.
29 . A method for preventing and/or treating a bacterial infection comprising the step of administering a therapeutically effective amount of the composition of claim 16 .
30 . The composition of claim 16 wherein the modified-release coating comprises a pH-dependent polymer coating for releasing a pulse of the active ingredient in said patient following a time delay of about 6 to about 12 hours after administration of said composition to said patient.